Acute renal and hepatic failure associated with allopurinol treatment

Clinical Nephrology

Volumn 70, Issue 6, 2008, Pages 523-526

  Fagugli, R M ^a   Gentile, G ^a   Ferrara, G ^a   Brugnano, R ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Allopurinol; Drug induced adverse effect; Molecular adsorbents recirculating sytem; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; IMMUNOGLOBULIN; INSULIN;

ABDOMINAL RADIOGRAPHY; ABNORMAL LABORATORY RESULT; ACUTE KIDNEY FAILURE; AGED; ALBUMIN DIALYSIS; ANGIONEUROTIC EDEMA; ARTICLE; ASCITES; BLISTER; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; COUGHING; DEHYDRATION; ECHOGRAPHY; FEMALE; FEVER; GLYCEMIC CONTROL; HEMATURIA; HUMAN; HUMAN TISSUE; INTENSIVE CARE; KIDNEY FUNCTION; KIDNEY INFECTION; OLIGURIA; PARENTERAL NUTRITION; PLEURA EFFUSION; SKIN BIOPSY; SORE THROAT; THORAX RADIOGRAPHY; TOXIC EPIDERMAL NECROLYSIS; URINALYSIS;

EID: 57349136855     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70523     Document Type: Article

References (18)

1. Abe R, Shimisu T, Shibati A et al. Toxic epidermal necrolysis and Steven-Johnson Syndrome are induced by soluble Fas ligand. Am J Pathol. 2003; 162: 1015-1020.
2. Athisakul S, Wangkaew S, Louthrenoo W. Inappropriate prescription of allopurinol in a teaching hospital. J Med Assoc Thai. 2007; 90: 889-894.
3. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Koida G. Nonallergic angioedema: role of bradykinin. Allergy. 2007; 62: 842-856.
4. Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000; 115: 149-153.
5. Becker DS. Toxic epidermal necrolysis. Lancet. 1998; 351: 1417-1420.
6. Chave TA, Mortimer NJ, Sladden MJ et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005; 153: 241-253.
7. French LE, Tschopp J. Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease, potential for therapeutic inhibition. Schweiz Med Wochenschr. 2000; 130: 1656-1661.
8. Hande KR, Noone RM, Stone WY. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984; 76: 47-56.
9. Heimbach D, Engrav L, Janet A et al. Toxic epidermal necrolysis: a step forward in treatment. JAMA. 1987; 257: 2171-2175.
10. Hsu SI. Biopsy-proven acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin. Pharmacotherapy 2001; 21: 1233-1239.
11. Lerner LH, Qureshi AA, Reddy B V et al. Nitric oxide synthase in toxic epidermal necrolysis and Steven-Jonson Syndrome. J Invest Dermatol. 2000; 114: 196-199.
12. Lupton GP Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol. 1979; 1: 365-374.
13. Massari PU, Hsu CH, Barnes R V et al. Familial hyperuncemia and renal disease. Arch Intern Med. 1980; 140: 680-684.
14. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricemia: results from the UK General Practice Research Database (GPRD). Rheumatology. 2005; 44: 1038-1042.
15. Mitzner SR, Stange J, Klammt S et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol. 2001; 12: S75-S82.
16. Paquet P, Piegard GE. Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and cal-protectin. Int J Mol Med. 2002; 10: 145-147.
17. Roujeau JC, Kelly JP Naldi L et al. Medication use and the risk of Stevens-Johnson Syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333: 1600-1607.
18. Viard-Leveugle I, Saurat JH, Frech LE. Evidences that nitric oxide is an upstream mediator of FasL-mediated keratinocyte apoptosis in toxic epidermal necrolysis. J Invest Dermatol. 2003; 121: Abs 743.